Teva has lost its appeal to maintain several patents on its 40 mg version of its multiple sclerosis drug Copaxone.
The drug is a key sales contributor for Teva. Sales of the short-acting version of the drug have plummeted with Mylan and Novartis generics out there. Sales for the 20mg and 40mg versions together amounted to $940 million in North America, this is down more than $700 million from last year's $1.65 billion.
Click here to view the entire article.